Get the Stockscreener App
28.50
3.18%
-0.935
Celldex Therapeutics Inc stock is traded at $28.50, with a volume of 627.37K.
It is down -3.18% in the last 24 hours and down -22.78% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$29.43
Open:
$29.28
24h Volume:
627.37K
Relative Volume:
0.34
Market Cap:
$2.24B
Revenue:
$866.00K
Net Income/Loss:
$-283.65M
P/E Ratio:
-6.678
EPS:
-4.267
Net Cash Flow:
$-226.25M
1W Performance:
-8.10%
1M Performance:
-22.78%
6M Performance:
-12.57%
1Y Performance:
+5.03%
1-Day Range:
$28.32
$29.28
1-Week Range:
$28.63
$31.35
52-Week Range:
$22.10
$45.14
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
28.50 | 2.24B | 866.00K | -283.65M | -226.25M | -4.267 |
VRTX
Vertex Pharmaceuticals Inc
|
490.56 | 124.34B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.75 | 85.74B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
752.60 | 77.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.22 | 50.51B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
191.28 | 41.00B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-26 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-26 | Upgrade | Barclays | Underweight → Overweight |
| Mar-23-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-13-25 | Initiated | Barclays | Underweight |
| Apr-28-25 | Initiated | Canaccord Genuity | Buy |
| Mar-20-25 | Initiated | Morgan Stanley | Overweight |
| Feb-13-25 | Initiated | UBS | Buy |
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
Law firm investigates Celldex Therapeutics for possible breach of fiduciary duties. - Pluang
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - PR Newswire
FMR LLC and Abigail P. Johnson Reveal 10.7% Stake in Celldex Therapeutics Inc. - Kalkine Media
An investment firm reports a passive stake of 8.4 million shares in Celldex Therapeutics (CLDX). - Stock Titan
Celldex Therapeutics Inc (TCE2.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Celldex Therapeutics: Trying To Put Its Troubled History Behind It (NASDAQ:CLDX) - Seeking Alpha
Celldex reports Phase 3 success as HC Wainwright rates Celldex Therapeutics stock Buy - AD HOC NEWS
Celldex Therapeutics stock reports strong Phase 3 trial results - AD HOC NEWS
Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
What Do Positive Barzolvolimab Results Mean for Celldex (NASDAQ:CLDX)? - Kalkine Media
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64 - Moomoo
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success? - Yahoo Finance
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Yahoo Finance
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CLDX) 2026-09-22 - Seeking Alpha
Celldex Therapeutics upgraded to Buy after posi... - Pluang
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CLDX) 2026-09-22 - Seeking Alpha
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results - Benzinga
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Benzinga
Celldex Therapeutics Shares Fall After Phase 3 Readout Despite Positive Trial Results - Quiver Quantitative
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses - finance.yahoo.com
Celldex sinks as safety concerns cloud immune drug results - BioPharma Dive
Celldex sinks as safety concerns cloud immune drug results - finance.yahoo.com
Celldex shares slip 15% as safety concerns cloud skin drug trial win - The Economic Times
Celldex's barzolvolimab hits primary and secondary endpoints in twin Phase III CSU trials - thepharmaletter.com
4 Biotech Stocks With Key Clinical Readouts Expected This Fall - tradingview.com
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials - finance.yahoo.com
Celldex stock falls after hives trial data (CLDX:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials - marketscreener.com
Celldex announces Phase 3 barzolvolimab trials meet primary and all key secondary endpoints - tradingview.com
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 - GlobeNewswire
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 - GlobeNewswire
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials - Yahoo Finance
Celldex Therapeutics stock gains as analysts target USD 56.42 - AD HOC NEWS
Celldex Reports Positive Phase 3 Results for Barzolvolimab - Intellectia AI
Celldex Therapeutics (Nasdaq:CLDX)Stock Analysis - simplywall.st
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - Eastern Progress
Celldex Therapeutics stock gains as analysts lift expectations - AD HOC NEWS
Celldex at Cantor conference: barzolvolimab data loom By Investing.com - Investing.com Canada
Celldex at Cantor conference: barzolvolimab data loom By Investing.com - Investing.com UK
Celldex to Present at Upcoming Investor Conference - The Manila Times
Celldex's investor talk will stream online Sept. 10 - Stock Titan
Celldex to Present at Upcoming Investor Conference - GlobeNewswire
Celldex to Present at Upcoming Investor Conference - Yahoo Finance
Celldex Therapeutics, Inc. Revenue Breakdown – NASDAQ:CLDX - TradingView
Celldex (CLDX) Quarterly Results: Profit Per Share Clears Its Benchmark on the Day; Market Reaction - vinanet.vn
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Celldex (CLDX) Momentum: Adds 0.32% to Close at $41.92 in the Current Update; Range Check - vinanet.vn
Celldex Therapeutics, Inc. $CLDX Shares Acquired by Bank of America Corp DE - MarketBeat
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celldex Therapeutics Inc Stock (CLDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PEPIN RONALD | SR. VP & CBO |
Dec 15 '25 |
Option Exercise |
5.47 |
19,333 |
105,714 |
20,097 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Dec 04 '25 |
Sale |
29.09 |
4,166 |
121,210 |
30,796 |
| FREDDY A JIMENEZ | Officer |
Dec 04 '25 |
Proposed Sale |
29.10 |
4,166 |
121,210 |
0 |
| Wright Richard M. | Former Officer |
Nov 13 '25 |
Option Exercise |
14.06 |
49,298 |
692,913 |
70,131 |
| Wright Richard M. | Former Officer |
Nov 13 '25 |
Sale |
24.00 |
49,298 |
1,183,177 |
20,833 |
| RICHARD M WRIGHT | Officer |
Nov 13 '25 |
Proposed Sale |
24.00 |
49,298 |
1,183,177 |
0 |
4.86%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):